Tactile Systems Technology, Inc., a medical technology company specializing in therapies for chronic disorders, reported its financial results for the second quarter of 2025. The company posted a total revenue increase of 7.8% year-over-year, reaching $78.9 million. The gross margin improved to 75% from 74% in the same quarter of 2024. Net income for the second quarter was $3.2 million, or $0.14 per diluted share, a decrease from $4.3 million, or $0.18 per diluted share, in the second quarter of 2024. Adjusted EBITDA was $7.7 million compared to $9.1 million in the prior-year period. Operating income decreased to $4.1 million from $5.8 million in the second quarter of 2024. Other income, primarily from interest, rose to $0.4 million from $0.2 million in the same quarter of the previous year. The income tax expense was reduced to $1.3 million, down from $1.8 million in Q2 2024. The company also highlighted the completion of its share repurchase program, having repurchased $16.5 million of stock. Additionally, Tactile Systems announced new data that demonstrates significant benefits of its Flexitouch Plus product for patients with head and neck cancer-related lymphedema. CEO Sheri Dodd expressed confidence that the company's momentum would continue into the second half of the year, supported by a favorable payer policy environment and healthy channel call points.